Sirtris Pharmaceuticals, Inc. Completes Initial Public Offering
30 May 2007 - 10:00PM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced today
the completion of its initial public offering of 6,900,000 shares
of common stock, which included 900,000 shares sold pursuant to the
underwriters' exercise in full of their over-allotment option. All
shares were sold at an initial public offering price of $10.00 per
share, resulting in aggregate net proceeds to Sirtris of
approximately $62.4 million after deducting underwriting discounts
and commissions and estimated offering expenses. J.P. Morgan
Securities Inc. acted as the sole book-running manager and CIBC
World Markets Corp., Piper Jaffray & Co., JMP Securities LLC,
and Rodman & Renshaw, LLC acted as co-managers for the
offering. A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on May
22nd, 2007. The public offering is being made by means of a written
prospectus. Copies of the final prospectus relating to the offering
may be obtained from: J.P. Morgan Securities Inc., Attention:
Prospectus Department, 4 Chase Metrotech Center, CS Level,
Brooklyn, NY 11245. Phone: (718) 242-8002. Email:
addressing.services@jpmorgan.com. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state in
which such offer, solicitation or sale would be unlawful prior to
their registration or qualification under the securities laws of
any such state. About Sirtris Pharmaceuticals Sirtris
Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our
drug candidates are designed to mimic certain beneficial health
effects of calorie restriction, without requiring a change in
eating habits, by activation of sirtuins, a recently discovered
class of enzymes. The company's headquarters are in Cambridge,
Massachusetts.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles